Vereos PET/CT

The Vereos PET/CT system combines anatomical CT imaging with functional PET imaging, utilizing image fusion software for comprehensive diagnostic insights in various medical fields. This system now includes an optional AI-powered PET Adaptive Reconstruction (AR) algorithm, which employs iterative reconstruction to enhance image quality by reducing noise and improving low contrast detectability compared to traditional methods.

The Vereos PET/CT system is an integrated diagnostic imaging device that combines Positron Emission Tomography (PET) and X-Ray Computed Tomography (CT) functionalities. CT technology provides anatomical cross-sectional images using X-rays, visualizing both high-density and soft tissues, while PET technology utilizes radiopharmaceuticals to generate images depicting the internal distribution of radioactivity, thereby offering insights into biochemical and metabolic processes within organs. The system facilitates the fusion of CT (anatomic) and PET (functional) images through Philips fusion viewer Image Fusion software, creating composite images crucial for therapeutic planning, disease severity assessment, and defining disease extent across oncology, cardiology, and neurology applications for a wide range of patient types and diseases. A key modification to the Vereos PET/CT system is the introduction of an optional Adaptive reconstruction algorithm known as PET Adaptive Reconstruction (PET AR), intended for offline reconstructions. This AI-powered algorithm iteratively reconstructs PET images to full convergence (Regularized Reconstruction), aiming to provide lower noise and improved low contrast detectability compared to the Ordered Subsets Expectation Maximization (OSEM) method. A software patch was released to manage the interface of PET AR, limiting its use to compatible scan types and enabling visual identification of PET AR reconstructed images. Non-clinical performance testing, including image quality verification by certified radiologists on sample clinical images, confirmed that the PET AR modification meets design requirements and maintains safety and effectiveness.

AI Regulatory Concerns

Powered by

Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.

• Q1. How does the PET Adaptive Reconstruction (AR) algorithm quantitatively compare to OSEM in terms of signal-to-noise ratio and contrast recovery across various lesion sizes and uptake levels?; What specific artificial intelligence or machine learning models underpin the PET AR algorithm, and what was the nature of the dataset used for its training and validation?; Are there specific radiopharmaceuticals or clinical indications (e.g., low-dose protocols, specific cancer types) where the PET AR algorithm demonstrates superior diagnostic performance or image clarity?; What is the computational overhead and typical processing time for the PET AR offline reconstruction compared to standard reconstruction methods, and are there specific hardware requirements?; How does the visual identifier for PET AR reconstructed images appear, and what mechanisms ensure users can easily differentiate these images from those produced by regular PET reconstruction, particularly in longitudinal studies?